AMENDMENT TO CO-EXCLUSIVE LICENSE AGREEMENTCo-Exclusive License Agreement • May 5th, 2011 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
Contract Type FiledMay 5th, 2011 Company IndustryThis Amendment to the Alnylam Co-Exclusive License Agreement is made as of March 14, 2011 (“Effective Date”), by and between Alnylam Pharmaceuticals, Inc. (“Alnylam”), on the one hand, and Whitehead Institute for Biomedical Research (“Whitehead”), Massachusetts Institute of Technology (“MIT”), and Max-Planck-Innovation GmbH (“MI”).
CO-EXCLUSIVE LICENSE AGREEMENTCo-Exclusive License Agreement • June 6th, 2005 • Edwards Lifesciences Corp • Orthopedic, prosthetic & surgical appliances & supplies • California
Contract Type FiledJune 6th, 2005 Company Industry JurisdictionThis LICENSE AGREEMENT (“Agreement”), dated as of June 2, 2005 (the “Effective Date”), is by and between Edwards Lifesciences PVT, Inc., a Delaware corporation (“Edwards”), on the one hand, and 3F Therapeutics, Inc., a Delaware corporation (“3F”), on the other hand. Each of Edwards and 3F may be referred to herein individually as a “Party” or collectively as the “Parties.”